ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

In this MEDtalk, Dr. Luis Paz-Ares, Chair of the Medical Oncology Department at Hospital Universitario 12 de Octubre, presents the phase 3 IMforte trial presented at the ASCO Congress 2025. The study demonstrated a significant and clinically meaningful improvement in progression-free and overall survival with lurbinectedin plus atezolizumab as first-line maintenance therapy for patients with extensive-stage small cell lung cancer, highlighting its potential as a new standard of care. On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin for this group af patients with disease progression on or after platinum-based chemotherapy.